The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


Stada Arzneimittel AGEU/1/21/1590/007

Main Information

Trade NameLibmyris
Active SubstancesAdalimumab
Dosage FormSolution for injection in pre-filled syringe
Licence HolderStada Arzneimittel AG
Licence NumberEU/1/21/1590/007

Group Information

ATC CodeL04AB04 adalimumab


License statusAuthorised
Licence Issued12/11/2021
Legal status*** AWAITING VALUE ***
Supply Status
Advertising Status*** AWAITING VALUE ***
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back